Clinical Trial

Dapagliflozin in STEMI

Study acronym: DAPA STEMI
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI. Eligible STEMI patients enrolled into the trial will be randomized to a SGLT2i or placebo. Cardiovascular Magnetic Resonance (CMR) imaging will be used to determine the infarct size.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-12-07; most recent amendment 2026-02-18.
Status change: Not Yet Recruiting → Recruiting 2025-04-02
Trial Details
NCT Number NCT06174753
Lead Sponsor Ottawa Heart Institute Research Corporation
Conditions ST Elevation Myocardial Infarction, Myocardial Infarction
Enrollment 256 participants
Start Date 2025-01-20
Primary Completion 2027-06 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-20